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The market trend analyses were published in 2016-2017.1-3 We also obtained relevant equity research reports from Morgan Stanley 
(N=9).4-12 The market trend analyses report 
empirical forecasts and describe factors 
related to growth rates, while the equity 
research reports are more descriptive in 
nature and incorporate expert opinions from 
interviews and other sources. Both types 
of reports stated they used primary data, 
including soliciting assessments from NGS 
experts, as well as publicly available data 
sources, although specific analytical methods 
are proprietary and thus not reported 
(reports were obtained through an agreement 
with the University of California and through 
personal communications).
Defining NGS Products 
and Clinical Markets
The NGS products market as a whole is 
categorized by specific uses (clinical, research, 
and agricultural) and products (instruments, 
consumables, bioinformatics, and services). 
We focus particularly on clinical NGS services. 
Figure 1 shows the size of markets and 
indicates how “markets” are defined. Results  
are reported using the compound annual 
growth rate (“CAGR”), a measure of growth 
over multiple time periods that takes into 
account compounding over the time-period.
Worldwide Market Size of 
NGS Products and Services
The market size for NGS products is growing. 
This market was nearly $5.9 billion in 2015 and 
is forecast to reach $13.8 billion by 2020 
(18.7% CAGR).2 A substantial and growing 
component of this market is represented 
by NGS services provided by companies that 
provide either raw data or a report to users. 
The total NGS services market was nearly 
$2.9 billion in 2015 and is forecast to reach 
$9.1 billion by 2020 (26.0% CAGR).2 One key 
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2trend is the transition from the use of 
Sanger-based sequencing to NGS sequencing, 
with an expected decrease in the market for 
Sanger-based instruments and consumables 
of almost 5% CAGR by 2020.2
Worldwide Market Size of 
Clinical NGS Services
Clinical NGS services is the fastest growing 
component of the overall NGS market 
(Figure 1). It encompasses diagnostics, risk 
prediction in cancer and other diseases 
(e.g. cardiovascular), therapy selection and 
monitoring, and screening. The global clinical 
NGS services market was $2.2 billion in 2015 
(37% of the total market) and is forecast to 
reach $7.7 billion by 2020 (28.1% CAGR).2 
Worldwide Market Size of Clinical 
NGS by Application
NGS tests are used for a variety of clinical 
applications worldwide (Figure 1). 
The reproductive health NGS test market 
is the largest market (54%) at $1.7 billion in 
2017, and is expected to reach $3.3 billion by 
2022 (13.8% CAGR).3 This consists of NIPT 
(the largest category), carrier screening, in 
vitro fertilization, and newborn screening.3 
The oncology NGS test market makes up the 
second largest market (27%) at $838.8 million 
in 2017, and is forecast to reach $4.1 billion 
by 2022 (37.3% CAGR).3 Other applications 
include Mendelian (rare) disorders, complex 
diseases, and transplant diagnostics.3 
Clinical applications can be further segmented 
by whether they are considered “current” 
or “emerging” markets. Current markets 
include cancer, HLA typing (for transplants), 
Mendelian disorders, metabolic and immune 
disorders, prenatal testing, and IVF. Emerging 
markets include cardiovascular, food-borne 
illness, neurological, and newborn screening.3 
Worldwide Market Size of 
Clinical NGS by Type of Test
The global clinical NGS market can also be 
segmented by the type of test. The largest 
market is for tests that sequence >50 genes but 
not the entire exome or genome. This market 
is estimated to be almost $2.6 billion in 2017 
and forecast to reach $5.2 billion in 2022 
(15.3% CAGR).3 However, the markets for 
whole exome and genome sequencing tests 
are rapidly increasing from their small base. 
The exome sequencing market is estimated at 
$152.2 million in 2017 and is forecast to reach 
a size of $1.3 billion in 2022 (53.9% CAGR), 
while the whole genome sequencing market is 
estimated at $32.9 million in 2017 but expected 
to reach $1.0 billion in 2022 (98.8% CAGR).3 
Figure 1: Market Size for NGS Sequencing Products, Clinical NGS Services, and Clinical NGS Applications
SOURCE [Authors' original figure, authors' interpretation of data from Bergin J. 2016. DNA Sequencing: Emerging Technologies and Applications, 
and Bergin J. 2017. Next-Generation Sequencing: Emerging Clinical Applications and Global Markets.] 
North American NGS 
Clinical Market
A significant portion of the NGS clinical 
market is based in North America (United 
States, Canada, and Mexico) which accounted 
for 43.7% ($1.3 billion) of the global clinical 
market in 2017. However, this percentage is 
forecast to decrease to 35% ($3.6 billion) in 
2022. While this region’s market is growing at 
an overall CAGR of 22.2% during this period, 
the rest of the world is growing at a faster 
rate.3 One reason is the growth of markets 
in Asia, especially China as well as India.3 
Another reason is that some experts believe 
that early cancer detection assays (e.g. liquid 
biopsy) will ramp up faster outside the US.4 
Factors Contributing to Greater 
Use of NGS and Future Growth
The combination of unmet clinical needs for 
better tools to predict, diagnose, treat, and 
monitor disease and increasingly efficient 
sequencing technologies are major factors 
driving the growth of NGS.1-12 Other factors 
driving growth include the increased 
understanding of the molecular basis of 
disease, patient demand, industry investment, 
and regulations that allow marketing of tests 
without FDA approval. 
However, within this overall growth there 
are important variations. For example, some 
experts believe that, within oncology, smaller, 
targeted panels will take market share away 
from large panels that measure hundreds 
of genes.7
Key Challenges to Be 
Addressed for NGS Markets
Despite rapid NGS test growth, there are a 
number of key issues that will need to be 
addressed to facilitate future growth. The still 
relatively high total costs of delivering NGS 
test results compared with other technology 
platforms, and limited coverage by payers, 
are key challenges. NGS remains relatively 
costly requiring initial equipment investment, 
specialized workforce requirements, and 
time-intensive variant interpretation. 
Our previous work has found limited and 
variable coverage of NGS tests by payers,13-18 
but the recent Centers for Medicare and 
Medicaid national coverage determination 
on Medicare coverage for tumor sequencing 
may portend increased coverage.19,20 Other 
challenges include the need to define and 
document clinical utility in peer-reviewed 
publications and the need for laboratory 
markets and regulatory processes to evolve 
with testing. There are also concerns that 
patients may face high out-of-pocket costs, 
while current patient assistance programs that 
cover these programs may be unsustainable. 
There is a need for clinical guidelines 
and consensus documents that provide 
evidence-based recommendations regarding 
test use in clinical practice. 
Summary
In summary, the NGS market is growing rapidly 
and is expected to continue its torrid pace. 
However, there are significant challenges that 
may dampen future growth if not addressed. n
References
1. Next Generation Sequencing Market. Rockville, MD: 
Kalorama Information, 2016 September. 
2. Bergin J. DNA Sequencing: Emerging Technologies 
and Applications. Wellesley, MA: BCC Research, 
2016  May. 
3. Bergin J. Next-Generation Sequencing: Emerging 
Clinical Applications and Global Markets (BIO126C). 
Wellesley, MA: BCC Research, 2017 June. 
4. Beuchaw S, Garcia L. Life Science Tools & 
Diagnostics: Are Liquid Biopsies Ready for Prime 
Time? New York, NY: Morgan Stanley Research, 
2016 April 18. 
5. Beuchaw S, Garcia L. Illumina Inc.: Clinical 
Slowdown More Concerning Than Europe. New 
York, NY: Morgan Stanley Research, 2016 April 19. 
6. Beuchaw S, Garcia L. Life Science Tools & 
Diagnostics: Molecular Diagnostics Expert Lunch 
Highlights. New York, NY: Morgan Stanley Research, 
2016 February 25. 
7. Beuchaw S, Garcia L. Life Science Tools & 
Diagnostics: Cancer Genomics Expert Call 
Highlights. New York, NY: Morgan Stanley Research, 
2016 June 1. 
8. Beuchaw S, Garcia L, Wachter Z, Rosenberg J. Life 
Science Tools & Diagnostics: AMP Diligence on 
ILMN, MYGN, NSTG, TTOO. New York, NY: Morgan 
Stanley Research, 2016 November 10. 
9. Beuchaw S, Garcia L, Wachter Z, Rosenberg J. Life 
Science Tools & Diagnostics: Expert Feedback on 
ILMN, TMO, QGEN. New York, NY: Morgan Stanley 
Research, 2016 November 14. 
10. Beuchaw S, Wachter Z. Illumina Inc.: ACSO 
Diligence: The Path to the TAM. New York, NY: 
Morgan Stanley Research, 2017 June 7. 
11. Beuchaw S, Wachter Z, Rosenberg J. Life Science 
Tools & Diagnostics: The Precision Medicine 
Paradox. New York, NY: Morgan Stanley Research, 
2016 December 5. 
12. Beuchaw S, Wachter Z, Rosenberg J. Life Science 
Tools & Diagnostics: Insight Day Expert Feedback: 
Positioning in Diagnostics. New York, NY: Morgan 
Stanley Research, 2017 April 7. 
13. Douglas MP, Parker SL, Trosman JR, Slavotinek 
AM, Phillips KA. Private Payer Coverage Policies 
for Whole Exome Sequencing (WES) in Pediatric 
Patients: Trends Over Time and Analysis of Evidence 
Cited Genet Med. 2018; In Press.
14. Trosman JR, Weldon CB, Douglas MP, Kurian AW, 
Kelley RK, Deverka PA, et al. Payer Coverage for 
Hereditary Cancer Panels: Barriers, Opportunities, 
and Implications for the Precision Medicine 
Initiative. J Natl Compr Canc Netw. 2017;15(2):219-28.
15. Clain E, Trosman JR, Douglas MP, Weldon CB, 
Phillips KA. Availability and payer coverage of 
BRCA1/2 tests and gene panels. Nat Biotechnol. 
2015;33(9):900-2.
16. Phillips KA, Deverka PA, Trosman JR, Douglas MP, 
Chambers JD, Weldon CB, et al. Payer coverage 
policies for multigene tests. Nat Biotechnol. 
2017;35(7):614-7.
17. Dervan AP, Deverka PA, Trosman JR, Weldon CB, 
Douglas MP, Phillips KA. Payer decision making for 
next-generation sequencing-based genetic tests: 
insights from cell-free DNA prenatal screening. 
Genet Med. 2017;19(5):559-67.
18. Chambers JD, Saret CJ, Anderson JE, Deverka PA, 
Douglas MP, Phillips KA. Examining Evidence in U.S. 
Payer Coverage Policies for Multi-Gene Panels and 
Sequencing Tests. Int J Technol Assess Health Care. 
2017:1-7.
19. Phillips KA, Trosman JR, Deverka PA, Quinn B, 
Tunis S, Neumann PJ, et al. Insurance coverage for 
genomic tests. Science. 2018;360(6386):278-9.
20. Phillips KA. Evolving Payer Coverage Policies on 
Genomic Sequencing Tests: Beginning of the End or 
End of the Beginning? JAMA. 2018;319(23):2379-2380.
Kathryn A. Phillips, PhD, Department of Clinical 
Pharmacy, Center for Translational and Policy Research 
on Personalized Medicine (TRANSPERS), University 
of California San Francisco, San Francisco; Philip R. 
Lee Institute for Health Policy, University of California 
San Francisco, San Francisco; Helen Diller Family 
Comprehensive Cancer Center, University of California 
San Francisco, San Francisco.
Michael P. Douglas, MS, Department of Clinical 
Pharmacy, Center for Translational and Policy Research 
on Personalized Medicine (TRANSPERS), University of 
California San Francisco, San Francisco
F
IE
L
D
 N
O
T
E
S
3
